Anestafoam incorporates the company’s proprietary Delevo Foam Technology and is indicated for the temporary relief of pain associated with minor cuts and scrapes, abrasions, skin irritation, sunburn, burns and insect bites. The company intends to sell the product primarily to dermatologists and podiatrists through its national field sales force. Anestafoam will also be available at retail drug stores and through internet distribution channels.
Michael Heffernan, president of Onset Therapeutics, said: “We expect this product to provide clinicians and patients with significant advantages over currently available topical anesthetics on the market. We have a number of additional products in our pipeline that utilize our Delevo Foam Technology that we intend to launch over the next couple of years.”